Prime editing: advances and therapeutic applications
Trends in Biotechnology · 2023-08 · 41 (8) · 1000-1012
DOI: 10.1016/j.tibtech.2023.03.004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Biotechnology, 2023-08. Verfasst von Zhihan Zhao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Leiden University Medical Center, Einthovenweg 20, 2300 RC Leiden, The Netherlands; The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW)…. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, CRISPR-Associated Protein 9. Die Arbeit wurde bisher 205-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Scholarship Council, Novo Nordisk Foundation.
Abstract (Originalsprache)
Clustered regularly interspaced short palindromic repeats-associated protein 9 (CRISPR-Cas)-mediated genome editing has revolutionized biomedical research and will likely change the therapeutic and diagnostic landscape. However, CRISPR-Cas9, which edits DNA by activating DNA double-strand break (DSB) repair pathways, is not always sufficient for gene therapy applications where precise mutation repair is required. Prime editing, the latest revolution in genome-editing technologies, can achieve any possible base substitution, insertion, or deletion without the requirement for DSBs. However, prime editing is still in its infancy, and further development is needed to improve editing efficiency and delivery strategies for therapeutic applications. We summarize latest developments in the optimization of prime editor (PE) variants with improved editing efficiency and precision. Moreover, we highlight some potential therapeutic applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Leiden University Medical Center, Einthovenweg 20, 2300 RC Leiden, The Netherlands; The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Leiden node, The Netherlands.
- Leiden University Medical Center, Einthovenweg 20, 2300 RC Leiden, The Netherlands; The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Leiden node, The Netherlands. Electronic address: p.mohanraju@lumc.n…
- Leiden University Medical Center, Einthovenweg 20, 2300 RC Leiden, The Netherlands; The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Leiden node, The Netherlands. Electronic address: n.geijsen@lumc.nl.
Förderung
- China Scholarship Council
- Novo Nordisk Foundation
Zitieren
APA
Zhao, Z., Shang, P., Mohanraju, P., & Geijsen, N. (2023). Prime editing: advances and therapeutic applications. Trends in Biotechnology, 41(8), 1000-1012. https://doi.org/10.1016/j.tibtech.2023.03.004
Vancouver
Zhao Z, Shang P, Mohanraju P, Geijsen N. Prime editing: advances and therapeutic applications. Trends in Biotechnology. 2023;41(8):1000-1012. doi:10.1016/j.tibtech.2023.03.004
BibTeX
@article{Zhao2023,
author = {Zhao, Zhihan and Shang, Peng and Mohanraju, Prarthana and Geijsen, Niels},
title = {Prime editing: advances and therapeutic applications},
journal = {Trends in Biotechnology},
year = {2023},
volume = {41},
number = {8},
pages = {1000--1012},
doi = {10.1016/j.tibtech.2023.03.004}
}
EUVIMED